Table 1

Characteristics for patients receiving penicillin V and macrolides

Penicillin VAll macrolidesP value
N1237514
Age, years (IQR)68.6 (58.4–80.5)71.3 (60.8–80.4)0.73
Male (%)764 (61.8)268 (52.1)<0.001
Income group (%)
 0 (lowest income quintile)124 (10.0)60 (11.7)
 1322 (26.0)131 (25.5)
 2369 (29.8)155 (30.2)0.71
 3231 (18.7)100 (19.5)
 4 (highest income quintile)189 (15.3)68 (13.2)
Comorbidity (%)
 Diabetes144 (11.6)74 (14.4)0.11
 Peripheral vascular disease50 (4.0)24 (4.7)0.55
 Previous MI97 (7.8)47 (9.1)0.37
 Ischaemic heart disease177 (14.3)61 (11.9)0.17
 Heart failure175 (14.2)70 (13.6)0.77
 Atrial fibrillation126 (10.2)45 (8.8)0.36
 COPD201 (16.3)121 (23.5)<0.001
 Cancer132 (10.7)43 (8.4)0.14
 Depression33 (2.7)15 (2.9)0.77
 Any psychiatric disease164 (13.3)57 (11.1)0.21
Charlson score (IQR)0 (0–2)1 (0–2)0.08
Concomitant pharmacotherapy (%)
 Lipid-lowering drugs127 (10.3)69 (13.4)0.06
 Loop diuretics342 (27.7)165 (32.1)0.06
 Beta-blockers202 (16.3)96 (18.7)0.23
 ACE inhibitors245 (19.8)122 (23.7)0.07
 Vitamin K antagonists71 (5.7)29 (5.6)0.94
 Antiplatelets20 (1.6)11 (2.1)0.45
 Antipsychotics125 (10.1)53 (10.3)0.90
 Antidepressants243 (19.6)109 (21.2)0.46
 Anxiolytics365 (29.5)155 (30.2)0.79
  • Dichotomous variables reported in absolute numbers and percentages.

  • Continuous variables reported in medians and IQR.

  • COPD, chronic obstructive pulmonary disease; MI, myocardial infarction.